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tumor’s molecular defect. Moreover, it should be feasible to
administer combination therapy targeting multiple interdepen-
dent points along a pathogenic pathway, or targeting separate
pathways. Following rebiopsy or molecular imaging, the effect of
the treatment can be monitored in real time (Liotta et al., 2001;
Petricoin et al., 2002).
Protein microarray technology
Basic definitions
At an elementary level, a protein array contains an array of
immobilized protein spots. Each spot can contain a homoge-
neous or heterogeneous set of “bait” molecules (Liotta and
Petricoin, 2000; MacBeath, 2002; Zhu and Snyder, 2003). A
spot on the array may display an antibody (Lal et al., 2002;
Templin et al., 2002; Wilson and Nock, 2003), a cell or phage
lysate (Paweletz et al., 2001; Zhu and Snyder, 2003), a recom-
binant protein or peptide (MacBeath and Schreiber, 2000), a
drug (Humphery-Smith et al., 2002), or a nucleic acid (Petach
and Gold, 2002; Schaeferling et al., 2002; Weng et al., 2002).
The array is queried with (1) a probe (labeled antibody or lig-
and), or (2) an unknown biologic sample (e.g., cell lysate or
serum sample) containing analytes of interest. By tagging the
query molecules with a signal-generating moiety, a pattern of
positive and negative spots is generated. For each spot, the
intensity of the signal is proportional to the quantity of applied
query molecules bound to the bait molecules. An image of the
spot pattern is captured, analyzed, and interpreted.
Functional assay methodology
Discovery efforts fueled by genomic and proteomic technolo-
gies have led to long lists of potential drug targets. Most of these
targets are proteins. There is an urgent need for function-based
assays to prioritize and validate candidate targets. Protein
arrays offer one means of conducting massive screening of
drugs (Greenbaum et al., 2002; Wilson and Nock, 2003). The
inhibitory properties of lead compounds on enzymatic drug tar-
gets can be analyzed in chip-based systems (Huels et al.,
2002). Protein arrays have been employed to measure the
enzyme activity profiles of the secreted and membrane pro-
Signal pathway and network profiling
Cancer is functionally a proteomic disease
At a functional level, cancer is both a proteomic and a genomic
disease. A cancer genetic defect is selected out during cancer
progression because the defect ultimately alters the protein net-
work generating a survival advantage for the cancer cell
(Hanahan and Weinberg, 2000; Hunter, 2000). Defective, hyper-
active, or dominating signal pathways may drive cancer growth,
survival, invasion, and metastasis (Liotta and Kohn, 2001). An
important goal of functional proteomics is to develop a “circuit
map” of the normal and diseased state of the cellular protein
network (Blume-Jensen and Hunter, 2001; Bowden et al., 1999;
Celis and Gromov, 2003; Hunter, 2000; Jeong et al., 2000).
Protein microarrays (Charboneau, 2002; Cutler, 2003; Ge,
2000; Lal et al., 2002; Liotta and Petricoin, 2000; MacBeath,
2002; MacBeath and Schreiber, 2000; Miller et al., 2003;
Paweletz et al., 2001; Wilson and Nock, 2003; Zhu and Snyder,
2001, 2003), an emerging technology that examines protein-
protein recognition events in a massively parallel mode, can be
used to profile the working state of cellular signal pathways in a
manner not possible by gene arrays. Herein we focus on the
analytical challenges faced by protein arrays and propose a
practical guide for optimizing construction and study design.
Individualized cancer therapy
We can envision a future technology that maps the state of a
protein signal pathway within a patient’s biopsied neoplastic
lesion (Liotta et al., 2001; Petricoin et al., 2002). Assume that
information flow through a specific node in the proteomic net-
work requires the phosphorylation of a known protein at a spe-
cific amino acid sequence. By measuring the proportion of
those protein molecules that are phosphorylated, we can infer
the level of activity of that signal node. If we compare this mea-
surement over time, or at stages of disease progression, or
before and after treatment, a correlation can be made between
the activity of the node and the biologic or disease state. A func-
tional map of the state of key pathways within that patient’s
tumor cells will become the starting point for personalized thera-
py. Under this scenario, therapy can be tailored to the individual
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teome of cancer cell lines (Jessani et al., 2002). In addition, new
chemical reagents have been developed that can profile and
identify the catalytic activity of enzymes in complex mixtures.
This combination of emerging technologies has the potential to
functionally map the state of enzyme networks before and after
perturbation (Ideker et al., 2001; Phizicky et al., 2003; Tyers and
Mann, 2003). Nevertheless, the measurement of enzymatic
activity levels, by themselves, is not sufficient to recapitulate the
activity level of a protein network in situ. This is because signal-
ing networks exist within the context of the inter- and intracellu-
lar microenvironment. Consequently, array-based technology
must incorporate measurements related to the status of
enzyme substrates and binding partners as they exist in vivo.
Spectrum of applications
Protein microarrays are currently being studied within several
fields relevant to cancer research: (1) Discovery of novel ligands
or drugs that bind to specific bait molecules on the array, (2)
multiplexing immunoassays to develop a miniature panel of
serum biomarkers or cytokines, and (3) profiling the state of
specific members of known signal pathways and protein net-
works. For categories 1 and 2, a variety of competing technolo-
gies already exist for protein discovery and multiplexed clinical
immunoassays.These include mass spectroscopy, ICAT, 2D gel
electrophoresis, bead capture, micro-ELISA (Celis and Gromov,
2003; Chen et al., 2002; Delehanty and Ligler, 2002; Pandey
and Mann, 2000), and 3rd generation clinical analyzers. In con-
trast, for category 3, the use of protein microarrays for network
profiling of cellular samples and clinical material offers the
greatest potential to gather knowledge not attainable by other
methods. Consequently, we will narrow our analysis to this spe-
cific application for clinical specimen profiling.
Classes of protein array technology
Currently, protein microarray formats fall into two major classes,
forward phase arrays (FPA) and reverse phase arrays (RPA),
depending on whether the analyte is captured from solution
phase or bound to the solid phase (Figure 1). In FPAs, capture
molecules, usually an antibody, are immobilized onto the sub-
stratum and act as a bait molecule. Each spot contains one type
of immobilized antibody or bait protein. In the FPA format, each
array is incubated with one test sample (e.g., a cellular lysate
from one treatment condition), and multiple analytes are mea-
sured at once. In contrast, the RPA format immobilizes an indi-
vidual test sample in each array spot, such that an array is
comprised of hundreds of different patient samples or cellular
lysates. In the RPA format, each array is incubated with one
detection protein (e.g., antibody), and a single analyte endpoint
is measured and directly compared across multiple samples.
Protein microarrays: Analytical challenges
Dynamic range of the proteome
Protein microarrays pose a significant set of analytical chal-
lenges not faced by gene arrays (Celis and Gromov, 2003; Lal et
al., 2002; Zhu and Snyder, 2003). The first serious obstacle is
the vast range of analyte concentrations to be detected. Protein
concentrations exist over a broad dynamic range (by up to a fac-
tor of 1010). To make the analysis even harder, a low abundance
analyte always exists in a complex biological mixture containing
a vast excess of contaminating proteins. Imagine that the speci-
ficity of a detection antibody is 99%, but a crossreacting protein
exists in a thousand fold (or greater) excess. For every one ana-
lyte molecule detected, there will be ten crossreacting contami-
nating molecules detected, and the signal over background will
be unacceptable.
Sensitivity requirements
PCR-like direct amplification methods do not exist for proteins.
Consequently, protein microarrays require indirect, and very
stringent, amplification chemistries (King et al., 1997; Kukar et
al., 2002; Morozov et al., 2002; Schweitzer et al., 2002).
Adequate sensitivity must be achieved (at least femtomolar
range), with acceptable background. Moreover, the labeling and
amplification method must be linear and reproducible to insure
reliable quantitative analysis. Finally, the amplification chemistry
must be tolerant to the large dynamic range of the analytes and
the complexity of the biologic samples.The biologic sample may
naturally contain biotin, peroxidases, alkaline phosphatases,
fluorescent proteins, and immunoglobulins, all of which can
substantially reduce the yield or background of the amplification
reaction.
Clinical samples
The clinical power of protein microarrays can only be realized if
the technology can be directly applied to biopsies, tissue cell
aspirates, or body fluid samples. In such cases, the input sam-
ple for protein microarrays is small in volume and low in analyte
concentration. A cubic centimeter of tissue may contain approx-
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Figure 1. Classes of protein microarray platforms
Forward phase arrays (top) immobilize a bait molecule such as an anti-
body designed to capture specific analytes with a mixture of test sample
proteins. The bound analytes are detected by a second sandwich anti-
body, or by labeling the analyte directly (upper right). Reverse phase
arrays immobilize the test sample analytes on the solid phase. An analyte-
specific ligand (e.g., antibody; lower left) is applied in solution phase.
Bound antibodies are detected by secondary tagging and signal amplifi-
cation (lower right).
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imately 109 cells. For a core needle biopsy or a cell aspirate, the
total number of cells available for analysis may be less than
100,000. Moreover, since tissues are highly heterogeneous, the
population of target cells may comprise a small percentage of
the total. Thus, for the analysis of cancer cells within a core
biopsy, only a few thousand cancer cells may be procurable.
Assuming that many proteins of interest, or their phosphorylat-
ed counterparts, exist in low abundance, the total concentration
of the analyte protein in the sample is obviously very low.
If the sensitivity of an analytical system is s (moles per vol-
ume), and the number of analyte molecules per cell is x, then
the threshold T for cell procurement per volume will be:
(x ≡ number of analyte molecules per cell [molecules/cell]; T ≡
threshold for cell procurement per volume [cells/volume]; s ≡
sensitivity of detection system [moles/volume]; A ≡ Avogadro’s
number [6.02 * 1023 molecules/mole]).
For example, if the abundance of a signal transduction or
transcription factor protein is in the range of 10,000 copies per
cell, and the analytical sensitivity of the detection is one femto-
mole/ml, then the number of cells T required for the assay will
be approximately 60,000 cells per ml, or 60 cells per microliter.
Consequently, if the analytic method does not have adequate
sensitivity, the number of cells required for the assay may not
exist within the range achievable for clinical utility.
Requirement for specific high affinity antibodies and 
ligands
Gene transcript profiling was catalyzed by the ease and
throughput of manufacturing probes with known, specific, and
predictable affinity constants. In contrast, the probes (e.g., anti-
bodies, aptamers, ligands, drugs) for protein microarrays can-
not be directly manufactured with predictable affinity and
specificity. The availability of high quality, specific antibodies or
suitable protein binding ligands is the limiting factor, and starting
point, for successful utilization of protein microarray technology
(Templin et al., 2002). Prior to use on any array format, antibody
specificity must be thoroughly validated (e.g., single appropriate
sized band on Western blot) using a complex biologic sample
similar to that applied and analyzed on the array. The degree of
posttranslational modifications or protein-protein interactions,
for an individual analyte protein, will contain critical biologic
meaning that cannot be ascertained by measuring the total con-
centration of the analyte. Consequently, a significant challenge
for protein microarrays is the requirement for antibodies, or sim-
ilar detection probes, that are specific for the modification or
activation state of the target protein. Sets of high-quality modifi-
cation state-specific antibodies are commercially available.
Unfortunately, high-quality antibodies are currently available for
only a small percentage of the known proteins involved in signal
networks and gene regulation. A significant challenge for coop-
erative groups, funding agencies, and international consortia is
the generation of large comprehensive libraries of fully charac-
terized specific antibodies, ligands, and probes. A major initiative
of HUPO (Human Proteome Organization) is the production and
qualification of antibody libraries that will be made available to
the scientific community (Hanash, 2003;Tyers and Mann, 2003).
Antibody affinity constrains array design
Each antibody-ligand interaction has its own unique affinity con-
stants (association and dissociation rates) that must be deter-
mined empirically, and in some cases laboriously. A number of
strategies are emerging that may speed up the process of dis-
covering and mass producing antibody/ligands with high speci-
ficity and affinity. The affinity constants constrain the linear
range of the assay. The linear detection range can only be
attained if the concentration of the analyte and antibody/ligand
are properly matched to the affinity. The analyte concentration
in many situations is, by definition, unknown, and may be the
experimental goal. A multiplexed format containing antibodies
with a wide range of affinities may not be able to handle a sam-
ple containing a wide span of analyte concentrations. Such a
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Figure 2. Reverse phase array design applied to analyze phosphorylation
states of signal pathway proteins
Following tissue procurement and microdissection, the cancer cells are
lysed and the entire cellular proteomic repertoire is immobilized onto a
solid phase. The immobilized analyte proteins containing those phosphory-
lated during signal transduction are probed with two classes of antibodies
that specifically recognize (1) the phosphorylated (modified) form of the
protein, or (2) the total protein regardless of its modified state. Each test
sample S1–S4 is arrayed and immobilized in a miniature dilution curve.
Upon signal development and imaging, the relative proportion of the ana-
lyte protein molecules, which are phosphorylated, can be compared
between test samples on the same array. For example, S3 has a low ratio of
phosphorylated to total protein, while sample S4 has a high ratio.
T = 
(A * s)
x
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format will achieve analytical linearity, and thus accuracy, only in
a small subset of array points for which the analyte concentra-
tion and cognate antibody affinity happen to match. This prob-
lem is greatly compounded for multiplexed sandwich assays.
Sandwich assays (Templin et al., 2002; Zhu and Snyder, 2003),
traditionally used for clinical immunoassays, do not require
direct tagging of the analyte. Instead, the analyte is captured
between an immobilized antibody recognizing one epitope, and
a second labeled antibody recognizing a different epitope on the
same analyte. This obviously limits the assay to proteins con-
taining two nonoverlapping accessible epitopes, and further
presupposes the existence of two validated antibodies.
Because there are two sets of affinity constants for each ana-
lyte, use of a sandwich format effectively doubles the stringency
placed on linearity across the array.
Native versus denatured proteins
The native versus denatured state of a protein analyte is anoth-
er critical factor that will affect the design and success of protein
array experiments. Many antibodies are made against peptides,
and require antigen denaturation in order to linearize the epi-
tope. On the other hand, denaturation will destroy informative
protein-protein interactions, and will abolish the binding of anti-
bodies that require native 3D conformation. A common experi-
mental strategy, which employs antibody arrays, requires direct
conjugation of the analyte proteins with a fluorescent, nucleic
acid, or biotin tag (Knezevic et al., 2001; Kukar et al., 2002; Lal
et al., 2002). The tag becomes the basis for subsequent detec-
tion or signal amplification. Unfortunately the conjugation
method itself may denature, damage, or mask the epitope.
Since every tagging reaction becomes an uncontrolled experi-
mental variable, the reproducibility of the tagging and the ulti-
mate effect on the analyte(s) of interest are inherently
imprecise. In addition, preservation of the native state may be
required for one set of experiments, while a second protocol
demands denaturation. The two different experiments will
require completely different lysing conditions, buffers, antibody
reagents, and substratum immobilization chemistries.
Protein array substrata
Most gene array platforms use planar silica substrata to immo-
bilize the probes (Miller et al., 2002). By analogy, initial attempts
P R I M E R
Table 1. Sources of technical errors and proposed solutions in microarray printing and detection
Issue Resolution
Printing array
Inconsistent spotting pattern Ensure print head assembly is clean and dry.
Check for debris under slide.
Confirm level of platen. 
Merging spots Allow spots to dry in between printing multiple hits/spot.
Missing spots Confirm calibration of print head assembly.
Ensure adequate sample volume. 
Compression of nitrocellulose Reset pin calibration to a level consistent with membrane contact, but not membrane damage.
Variability in slide surface Visually inspect commercial and in-house slide preparations for consistency in the slide membrane surface.
Processing/storage
Water droplets on slide Store printed slides in the dark at −20°C in a container with desiccant. 
Allow slides to reach room temperature prior to staining.
Detection technologies
Little or absent staining Inadequate protein content of sample.
Confirm addition and concentration of primary and secondary antibodies.
Confirm species cross-reactivity of antibodies for the tissue source.
For horseradish peroxidase (HRP) detection systems, avoid reagents containing sodium azide in 
concentrations greater than 15 mM/l.
Expired/defective reagents Confirm storage conditions of reagents.
Discard expired reagents.
Dissociation of primary antibody Optimize antibody dilution for type of antibody.
Background staining Ensure adequate blocking of nitrocellulose membrane prior to detection protocols.
Avoid slide drying during chromogenic detection.
Use humidifiers or larger reagent volumes to prevent drying during incubations.
Prepare a more dilute secondary antibody solution. Nonspecific binding to the Fc portion of IgG 
may be limited by using a F(ab) fragment as a secondary antibody.
No discrimination between Primary antibody may not be specific for protein of interest.
Confirm specificity of primary antibody by Western blot.
The antibody should produce a single band at the designated molecular weight on a Western blot.
Sample
Viscous sample Dilute samples for adequate sample delivery.
Limited protein quantity Avoid degradation of proteins. Store samples at −80°C.
Add protease inhibitors to extraction buffers.
background and target
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at protein microarrays have used the same substrata and spot-
ting equipment. While this approach may be successful for high
abundant or recombinant analytes, a planar substratum cannot
attain sufficient surface area per spot for femtomolar detection
of analyte proteins in biologically relevant samples. Optimal
substrata for protein microarrays must have high binding capac-
ity, high surface area, and intrinsically low background signal
(Seong, 2002; Wilson and Nock, 2003). The choice of substra-
tum will dictate the immobilization chemistries employed. This,
in turn, will impact on the native state, or appropriate orientation
of the immobilized protein bait or capture molecule. For exam-
ple, if the immobilized capture molecule is an antibody, it is high-
ly desirable to position each antibody with its ligand binding
domain upright.
Need for quantitation
Accuracy and precision are paramount for protein microarrays.
A small shift in a signaling pathway in the protein circuitry can
dramatically affect the ultimate biologic outcome. This issue is
pronounced for specific pathologic states such as premalignant
progression. A subtle shift in the birth or death rate of hyper-
plastic cells, integrated over many years, can determine the fate
of a premalignant lesion.The strength of immunohistochemistry
(and by extension multiplexed tissue arrays) is to provide infor-
mation about histomorphological and subcellular localization.
However, immunohistochemistry is inherently subjective and
nonquantitative, and may not be adequately sensitive for low
abundance analytes. Variability in immunohistochemistry can
be imparted by tissue handling and fixation, accessibility of the
antigen epitope (antigen retrieval treatments), and cellular het-
erogeneity. In the face of the quantitative limitations of immuno-
histochemistry, investigators are intrigued with the promise of
protein microarrays and the hope of obtaining high-throughput
multiplexed quantitative analysis of biologic samples.
Reverse phase arrays (RPA) offer advantages for transla-
tional research
RPAs address analytical challenges
We have developed RPAs as a format that addresses the analyt-
ical challenges stated above (Charboneau, 2002; Paweletz et
al., 2001; Petricoin et al., 2002) (Figure 2). RPAs can achieve
adequate sensitivity for small samples. This format has been
successfully applied to analyze the state of the prosurvival,
apoptosis, and mitogenesis pathways within microdissected pre-
malignant lesions, compared to adjacent normal epithelium,
invasive carcinoma, and host stroma (Paweletz et al., 2001).
Each spot within an RPA contains an immobilized bait zone mea-
suring only a few hundred microns in diameter and containing a
solubilized sample of the cellular material itself. The high sensi-
tivity of RPAs is in part because the detection probe (e.g., anti-
body) can be tagged and the signal amplified, independent from
the immobilized analyte protein. Amplification chemistries avail-
able take advantage of methods developed for highly sensitive
3rd generation commercial clinical immunoassays (Bobrow et al.,
1989, 1991; Hunyady et al., 1996; King et al., 1997). For exam-
ple, coupling the detection antibody with highly sensitive tyra-
mide-based avidin/biotin signal amplification systems can yield
detection sensitivities down to fewer than 1000–5000 mole-
cules/spot. A biopsy of 10,000 cells can yield 100 RPA arrays.
Each array can be probed with a different antibody.
Precision and linearity of RPAs
Using commercially available automated equipment, RPAs
exhibit excellent within-run and between-run analytical preci-
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Figure 3. Validation of reverse phase protein microarrays for microdissected lysates
A: Annexin-1 stained slide of triplicate arrayed dilution curves ranging over one log of cellular equivalents loaded per spot.
B: Linearity between immobilized protein lysate and signal intensity between seven replicate slides.
C: Intra- and interspot coefficient of variance % CV. RFU, relative fluorescence units. 
See Paweletz et al., 2001.
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sion with greater than 6 cell equivalents (3%–10% c.v.) (Figure
3). RPAs do not require direct labeling of the sample analyte,
and do not utilize a two-site antibody sandwich.Therefore, there
is no experimental variability introduced due to labeling yield,
efficiency, or epitope masking. As each array is comprised of
dozens or hundreds of experimental samples, subtle differ-
ences in an analyte can be measured, because each sample is
exposed for the same amount of time to the same concentration
of primary and secondary antibody and amplification reagents.
RPA platforms can utilize reliable commercially available auto-
mated strainers designed for immunohistochemistry.
Miniature dilution curves
A critical factor in determining the linearity of a protein array,
common to all immunoassays, is the match between the anti-
body probe concentration (affinity constant) and the unknown
concentration of the analyte (Humphery-Smith et al., 2002).
Another special and important attribute of the RPA is that each
sample is applied in a miniature dilution curve on the array
(Figure 2). In principle, a calibration curve is developed for each
antibody, for each sample, and for each analyte concentration.
This provides an improved means of matching the antibody
concentration with the analyte concentration so that the linear
range of each analyte measurement is insured.
Protein microarrays: A practical guide
Selection and validation of antibodies
The most important starting point for the development of any
protein array method is the selection of antibodies with high
specificity and adequate affinity. If the experimental focus is cel-
lular signaling analysis, then the platform will require at least
two different kinds of antibodies for each protein. One antibody
is chosen to recognize the phosphorylated form of the protein,
and the second recognizes the protein regardless of its phos-
phorylation status. Prior to use on any array, each antibody must
be validated for specificity and sensitivity. Specificity should be
performed by Western blotting, preferably using the same class
of material that will be applied to the array. The optimal criterion
for specificity is a single band at the appropriate molecular
weight, which can be competed with the immunizing antigen.
The optimal dilution of the primary antibody will be dictated by
the relative binding affinity. This can only be determined empiri-
cally using a known concentration of reference antigen or con-
trol lysate. We have validated over 100 (out of approximately
400) commercially available phosphospecific or modification
specific antibodies covering mitogenesis, survival, apoptosis,
differentiation, and motility related pathways. The full list of anti-
bodies, the commercial suppliers, and initial working dilutions is
available for download at http://clinicalproteomics.steem.com.
Tissue microdissection and lysate conditions
Cellular signaling processes are dominated by the context of
the cell type and the tissue microenvironment (Liotta and Kohn,
2001). Microdissection (Emmert-Buck et al., 1996) of the het-
erogeneous tissue sample is therefore required to obtain mean-
ingful information. In order to reduce protein degradation by
phosphatases and proteinases, the optimal protocol is to snap-
freeze the tissue immediately after procurement. Protein extrac-
tion buffers with ionic and nonionic detergents will effectively
solubilize the cells, while preserving phosphorylated proteins.
Moreover, laser capture microdissection can employ proteinase
and phosphatase inhibitors directly in the fixation and staining
baths (Simone et al., 2000).
Arraying and arrayers
Protein microarrays are printed using the same technology
used for DNA microarrays, but the protein array layout is vastly
different from a typical DNA array. Both printing technologies
transfer sample fluid from a microtiter plate onto a substratum,
usually a coated glass slide. The substratum requirements for
protein arrays are (1) high binding capacity, (2) minimum effect
on the protein structure, and (3) low background (Table 1).
Nitrocellulose coated glass slides are a common substratum for
protein arrays (FAST slides, Schleicher & Schuell BioSciences
or Grace Biolabs). Proteins bind to nitrocellulose via electrosta-
tic interactions in an irreversible manner (Stillman and
Tonkinson, 2000). The nitrocellulose polymer coating of FAST
slides permits protein binding capacities of 75–150 ug/cm2 in a
volume of 0.3–2 nl/spot. Protein arrays may also be printed in
sector formats. A sector array consists of multiple small pads of
substratum on a slide. A reservoir placed around each sector
permits a different antibody to be used for probing the samples.
The sector format miniaturizes the array, providing an increased
signal/noise ratio.
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Figure 4. Idealized reverse phase array format
Triplicate samples are printed in dilution curves representing undiluted, 1:2,
1:4, 1:8, and 1:16 dilutions. The sixth spot represents a negative control, con-
sisting of extraction buffer without sample. Each set of triplicate spots rep-
resents a patient sample before or after treatment, or microdissected
normal, premalignant, or stromal tissue cells. A reference lysate or control
lysate is printed on each array for monitoring assay performance. A recom-
binant antigen is printed on each array for comparative quantitation of
patient samples. Altering spot size and/or spot spacing may vary array
capacity.
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Signal amplification and detection
A variety of protein array labels and amplification chemistries
are available (King et al., 1997; Kukar et al., 2002; Morozov et
al., 2002; Schweitzer et al., 2002; Wiese, 2003). These include
fluorescent, radioactive, luminescent, and colorimetric read-
outs. Chromogenic, fluorometric, and luminescent detection
methods may be used with FAST slides with an adequate sig-
nal/noise ratio. Amplification can be achieved by enzymatic
cleavage of colorimetric, luminescent, and fluorescent sub-
strates. Several amplification systems employ coupling of nucle-
ic acids to proteins, and thereby take advantage of the PCR
method. Amplification is absolutely required to achieve the sen-
sitivity adequate for routine analysis of relatively low abundance
proteins.
Determination of baseline sensitivity
The baseline sensitivity of detection dictates the minimum num-
ber of cells T (see above) that can be profiled on the array. Using
a dilution curve of a known concentration of reference antigen,
the first step is to determine the intra- and inter-slide coeffi-
cients of variance. Baseline sensitivity is defined as a signal two
standard deviations above background. Using the same amplifi-
cation or labeling chemistries, the baseline sensitivity is differ-
ent for each antibody choice.This is because each antibody has
a different affinity and background binding, and its cognate anti-
gen falls within a different dynamic range.
Bioinformatic analysis of protein array data
A variety of bioanalytical methods have been successfully used
for protein microarrays (Brazma et al., 2001; Carlisle et al.,
2000; Cutler, 2003; Miller et al., 2003; Sreekumar et al., 2001).
Analyzing RPAs presents a new set of challenges, compared
with conventional spotted arrays. Using the flexible, open-
source program PSCAN (Carlisle et al.), we developed an
analysis strategy tailored specifically to these arrays (Figure 5).
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Figure 5. Scanning and bioinformatic analysis of reverse phase arrays
The example shown displays a cluster analysis of microdissected human breast cancer and normal breast epithelium (vertical axis) compared across the
phosphorylation states of a series of proteins within the EGF-receptor family signal pathway (horizontal axis lower right). The data collection steps depicted
are described in the text.
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Array spot placement
The first challenge relates to detecting the placement of sample
spots on the array. The spot placement is constrained by the pin
configuration of the printer, and by the organization of serial
dilutions in the original plates, and may be controlled by pro-
gramming the printer robot. Currently, determining the spot
locations within each image requires operator assistance, but
this process could become fully automated with the inclusion of
reference spots. Determination of background intensity is facili-
tated by reserving an adequate number of “empty” spots within
the image. Spot intensity is usually estimated by integrating over
a fixed spot area. Spot size should also be monitored.
Systematic change in spot size with dilution may signal a
change in viscosity of the printed sample, and may require a
more sophisticated intensity estimation algorithm.
Normalizing spot intensity
Spot intensities for points on each dilution curve need to be
reduced to a single value corresponding to the amount of pro-
tein present in the sample. Assuming that intensity above back-
ground is proportional to protein concentration, the intensity
versus log-dilution plot should ideally appear as an exponential
decay curve. With a sufficient number and quality of data points,
well-known curve-fitting techniques are ideal for determining
the parameters of relative protein concentration, background
intensity, and decay constant, as well as for checking the overall
fit to the curve. Deviations from ideality (nonmonotonicity, high-
dose “hook” effects, nonexponential behavior, too few points,
trends, or gradients in background intensity) are sometimes
observed in RPA assays, and require special attention. Robust
estimation techniques can be used to address the presence of
outliers in the data, caused for example by printing dropouts or
flares. Observing an exponential decay rate different from unity
suggests nonlinearity in the intensity-dilution curve. Parallelism
between multiple curves should be checked, and samples that
deviate should be flagged. Apparent saturation of intensity for
high concentration (low dilution) points may suggest use of only
the low-dose portion of the curve.
Correction for internal sources of variability
After estimating the parameters for each dilution curve, it may
then be necessary to correct for intensity gradients between dif-
ferent printer pins or across the slide.Thoughtful planning of the
slide layout will have a big impact in such situations (Figure 4).
When each set of dilutions for a sample is printed contiguously,
it may be possible to correct for such trends by subtracting local-
ly averaged values for nearby samples, yielding relative, locally
corrected values for protein concentration. Finally, as the overall
intensity on each slide or chip varies significantly with the partic-
ular specific antibody, it may be necessary to further adjust the
values for each array, before combining into a single study.
Public software for protein array analysis
Our analytical protocol for a specific RPA study based on public
software is outlined below (Figure 5). Multiple RPAs, each ana-
lyzing a different phosphorylated protein, are scanned, spot
intensities are calculated and normalized, and the dilution curve
is collapsed to a single intensity value (Figure 5). This value is
then assigned a relative normalized intensity value referenced
to the other patient samples on the array. The data output is in
the form suitable for traditional unsupervised and supervised
learning systems. In this way, protein array data is displayed as
traditional “heat maps” and can employ powerful Bayesian clus-
tering analysis for signal pathway profiling.
Protein microarrays can be applied to clinical material
In the current art, protein microarrays can be applied to serum
(Miller et al., 2003) and tissue samples (Knezevic et al., 2001;
Paweletz et al., 2001) with acceptable reliability. FPAs containing
up to 184 antibodies have been successfully applied to the
analysis of microdissected biotinylated cellular lysates (Miller et
al., 2003) and serum antibody or biomarker screening (Knezevic
et al., 2001). The major weakness of current FPAs (antibody
arrays) is the low sensitivity and the between-run variability (Lal
et al., 2002; Wilson and Nock, 2003). RPAs, described above,
have achieved the sensitivity and precision acceptable for the
analysis of clinical tissue biopsy specimens. A perceived draw-
back of RPA is the fact that the arrays, since they are composed
of experimental samples, cannot be printed and stored ahead of
time. This potential drawback is overcome by the improved abili-
ty to match the antibody and analyte in the linear range, and the
lack of the requirement for analyte tagging. A major weakness of
both formats is the limited (but growing) availability of high-affini-
ty specific antibodies for a multitude of important signal pathway
molecules and cancer-related gene products.
Ongoing clinical research trials at the National Cancer
Institute Warren G. Magnuson Clinical Center are currently
employing RPAs. According to the IRB-approved study design,
core needle biopsies are procured before and after therapy, and
at the time of potential recurrence. For three trials underway,
RPAs are being used to study the change in the phosphorylated
or cleaved state of selected proteins within EGF-receptor-family
triggered, prosurvival, mitogenesis, motility, and apoptosis-
related pathways. The first goal of the trials is to fully evaluate
the strengths and limitations of the technology, particularly for
sample procurement and processing. The second goal is to
transition from hypothesis generation to prospective individual
selection of combinatorial therapy. Thus, step-by-step, the hope
is to realize the concept of patient-tailored therapy.
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